These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 33447958

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL, Antunes P, Ferreira LN, Pereira LN, Ramos-Goñi JM.
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [Abstract] [Full Text] [Related]

  • 3. Valuation of the EQ-5D-3L in Russia.
    Omelyanovskiy V, Musina N, Ratushnyak S, Bezdenezhnykh T, Fediaeva V, Roudijk B, Purba FD.
    Qual Life Res; 2021 Jul; 30(7):1997-2007. PubMed ID: 33713323
    [Abstract] [Full Text] [Related]

  • 4. Valuation of the EQ-5D-3L in Jordan.
    Al Rabayah A, Roudijk B, Purba FD, Rencz F, Jaddoua S, Siebert U.
    Eur J Health Econ; 2024 Sep 03. PubMed ID: 39225720
    [Abstract] [Full Text] [Related]

  • 5. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values.
    Fitriana TS, Roudijk B, Purba FD, Busschbach JJV, Stolk E.
    Pharmacoeconomics; 2022 Dec 03; 40(Suppl 2):157-167. PubMed ID: 36348155
    [Abstract] [Full Text] [Related]

  • 6. Value Set for the EQ-5D-Y-3L in Hungary.
    Rencz F, Ruzsa G, Bató A, Yang Z, Finch AP, Brodszky V.
    Pharmacoeconomics; 2022 Dec 03; 40(Suppl 2):205-215. PubMed ID: 36123448
    [Abstract] [Full Text] [Related]

  • 7. Estimating an EQ-5D-Y-3L Value Set for Brazil.
    Espirito Santo CM, Miyamoto GC, Santos VS, Ben ÂJ, Finch AP, Roudijk B, de Jesus-Moraleida FR, Stein AT, Santos M, Yamato TP.
    Pharmacoeconomics; 2024 Sep 03; 42(9):1047-1063. PubMed ID: 38954389
    [Abstract] [Full Text] [Related]

  • 8. Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study.
    Al-Jedai A, Almudaiheem H, Al-Salamah T, Aldosari M, Almutairi AR, Almogbel Y, AlRuthia Y, Althemery AU, Alluhidan M, Roudijk B, Purba FD, Awad N, O'jeil R.
    Value Health; 2024 May 03; 27(5):552-561. PubMed ID: 38342365
    [Abstract] [Full Text] [Related]

  • 9. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
    Pickard AS, Law EH, Jiang R, Pullenayegum E, Shaw JW, Xie F, Oppe M, Boye KS, Chapman RH, Gong CL, Balch A, Busschbach JJV.
    Value Health; 2019 Aug 03; 22(8):931-941. PubMed ID: 31426935
    [Abstract] [Full Text] [Related]

  • 10. Valuing Health State: An EQ-5D-5L Value Set for Ethiopians.
    Welie AG, Gebretekle GB, Stolk E, Mukuria C, Krahn MD, Enquoselassie F, Fenta TG.
    Value Health Reg Issues; 2020 Sep 03; 22():7-14. PubMed ID: 31683254
    [Abstract] [Full Text] [Related]

  • 11. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
    Law EH, Pickard AS, Xie F, Walton SM, Lee TA, Schwartz A.
    Med Decis Making; 2018 Nov 03; 38(8):968-982. PubMed ID: 30403577
    [Abstract] [Full Text] [Related]

  • 12. Estimating an EQ-5D-Y-3L Value Set for China.
    Yang Z, Jiang J, Wang P, Jin X, Wu J, Fang Y, Feng D, Xi X, Li S, Jing M, Zheng B, Huang W, Luo N.
    Pharmacoeconomics; 2022 Dec 03; 40(Suppl 2):147-155. PubMed ID: 36396878
    [Abstract] [Full Text] [Related]

  • 13. Dutch Tariff for the Five-Level Version of EQ-5D.
    M Versteegh M, M Vermeulen K, M A A Evers S, de Wit GA, Prenger R, A Stolk E.
    Value Health; 2016 Jun 03; 19(4):343-52. PubMed ID: 27325326
    [Abstract] [Full Text] [Related]

  • 14. The EQ-5D-3L Valuation Study in Pakistan.
    Malik M, Gu NY, Hussain A, Roudijk B, Purba FD.
    Pharmacoecon Open; 2023 Nov 03; 7(6):963-974. PubMed ID: 37702988
    [Abstract] [Full Text] [Related]

  • 15. The EQ-5D-5L Valuation study in Thailand.
    Pattanaphesaj J, Thavorncharoensap M, Ramos-Goñi JM, Tongsiri S, Ingsrisawang L, Teerawattananon Y.
    Expert Rev Pharmacoecon Outcomes Res; 2018 Oct 03; 18(5):551-558. PubMed ID: 29958008
    [Abstract] [Full Text] [Related]

  • 16. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
    Shiroiwa T, Ikeda S, Noto S, Igarashi A, Fukuda T, Saito S, Shimozuma K.
    Value Health; 2016 Oct 03; 19(5):648-54. PubMed ID: 27565282
    [Abstract] [Full Text] [Related]

  • 17. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
    Kreimeier S, Oppe M, Ramos-Goñi JM, Cole A, Devlin N, Herdman M, Mulhern B, Shah KK, Stolk E, Rivero-Arias O, Greiner W.
    Value Health; 2018 Nov 03; 21(11):1291-1298. PubMed ID: 30442276
    [Abstract] [Full Text] [Related]

  • 18. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
    Golicki D, Jakubczyk M, Graczyk K, Niewada M.
    Pharmacoeconomics; 2019 Sep 03; 37(9):1165-1176. PubMed ID: 31161586
    [Abstract] [Full Text] [Related]

  • 19. The EQ-5D-5L valuation study for Trinidad and Tobago.
    Bailey H, Jonker MF, Pullenayegum E, Rencz F, Roudijk B.
    Health Qual Life Outcomes; 2024 Jul 02; 22(1):51. PubMed ID: 38956543
    [Abstract] [Full Text] [Related]

  • 20. Using Time Trade-Off Values to Estimate EQ-5D-Y Value Sets: An Exploratory Study.
    Yang Z, Jiang J, Wang P, Wu J, Fang Y, Feng D, Xi X, Luo N.
    Value Health; 2023 Jul 02; 26(7):968-973. PubMed ID: 36921897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.